Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Mar 25

PMID 35328227

Authors

Rossella Bruno

Anello Marcello Poma

Greta Ali

Claudia Distefano

Agnese Proietti

Antonio Chella

Marco Lucchi

Franca Melfi

Renato Franco

Gabriella Fontanini

Affiliations

Soon will be listed here.

Abstract

Biphasic is the second most common histotype of pleural mesothelioma (PM). It shares epithelioid and sarcomatoid features and is challenging to diagnose. The aim of this study was to identify biphasic PM markers to improve subtyping and prognosis definition. The expression levels of 117 cancer genes, evaluated using the nanoString system, were compared between the three major histotypes (epithelioid, sarcomatoid, and biphasic), and expression differences within biphasic PM were evaluated in relation to the percentage of epithelioid components. Biphasic PM overexpressed and in comparison to sarcomatoid, and and in comparison to epithelioid PM. , , , , and were deregulated among all histotypes, leading to the hypothesis of a gradual expression from epithelioid to sarcomatoid PM. According to gene expression, biphasic PM samples were divided in two clusters with a significant difference in the epithelioid component. , , and were overexpressed in the biphasic group with a low percentage of epithelioid component. Survival analysis using TCGA data showed that high and expression levels correlate with poor survival in PM patients. Herein, we identified markers with the potential to improve diagnosis and prognostic stratification of biphasic PM, which is still an orphan tumor.

Citing Articles

Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series.

Bruno R, Poma A, Ali G, Proietti A, Ribechini A, Chella A Cancers (Basel). 2023; 15(23).

PMID: 38067238 PMC: 10705177. DOI: 10.3390/cancers15235534.

New Immunohistochemical Markers for Pleural Mesothelioma Subtyping.

Di Stefano I, Ali G, Poma A, Bruno R, Proietti A, Niccoli C Diagnostics (Basel). 2023; 13(18).

PMID: 37761312 PMC: 10529020. DOI: 10.3390/diagnostics13182945.

References

Creaney J, Robinson B . Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment. Chest. 2016; 152(1):143-149. DOI: 10.1016/j.chest.2016.12.004. View

Guan Z, Zhang J, Song S, Dai D . Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagn Pathol. 2013; 8:110. PMC: 3737241. DOI: 10.1186/1746-1596-8-110. View

Bueno R, Stawiski E, Goldstein L, Durinck S, De Rienzo A, Modrusan Z . Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016; 48(4):407-16. DOI: 10.1038/ng.3520. View

Bruno R, Ali G, Giannini R, Proietti A, Lucchi M, Chella A . Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. Oncotarget. 2016; 8(2):2758-2770. PMC: 5356839. DOI: 10.18632/oncotarget.13174. View

Pastan I, Hassan R . Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014; 74(11):2907-12. PMC: 4062095. DOI: 10.1158/0008-5472.CAN-14-0337. View

Abayasiriwardana K, Wood M, Prele C, Birnie K, Robinson B, Laurent G . Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model. Biochem Biophys Res Commun. 2019; 510(2):198-204. DOI: 10.1016/j.bbrc.2019.01.057. View

Robinson B . Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2013; 1(4):491-6. PMC: 3741803. DOI: 10.3978/j.issn.2225-319X.2012.11.04. View

Ryu D, Lee C . Expression quantitative trait loci for PI3K/AKT pathway. Medicine (Baltimore). 2017; 96(1):e5817. PMC: 5228698. DOI: 10.1097/MD.0000000000005817. View

Ramundo V, Zanirato G, Aldieri E . The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma. Int J Mol Sci. 2021; 22(22). PMC: 8621591. DOI: 10.3390/ijms222212216. View

10.

Abril-Rodriguez G, Torrejon D, Liu W, Zaretsky J, Nowicki T, Tsoi J . PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer. 2021; 1(1):46-58. PMC: 8340852. DOI: 10.1038/s43018-019-0003-0. View

11.

Meyerhoff R, Yang C, Speicher P, Gulack B, Hartwig M, DAmico T . Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015; 196(1):23-32. PMC: 4430361. DOI: 10.1016/j.jss.2015.01.043. View

12.

Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim T . A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience. J Thorac Oncol. 2015; 10(11):1634-41. DOI: 10.1097/JTO.0000000000000661. View

13.

Naija A, Merhi M, Inchakalody V, Fernandes Q, Mestiri S, Prabhu K . The role of PAK4 in the immune system and its potential implication in cancer immunotherapy. Cell Immunol. 2021; 367:104408. DOI: 10.1016/j.cellimm.2021.104408. View

14.

Grassel S, Bauer R . Collagen XVI in health and disease. Matrix Biol. 2012; 32(2):64-73. DOI: 10.1016/j.matbio.2012.11.001. View

15.

Zhang C, Liu S, Wang X, Liu H, Zhou X, Liu H . COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma. Biomed Res Int. 2021; 2021:5320941. PMC: 7803428. DOI: 10.1155/2021/5320941. View

16.

Alcala N, Mangiante L, Le-Stang N, Gustafson C, Boyault S, Damiola F . Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine. 2019; 48:191-202. PMC: 6838392. DOI: 10.1016/j.ebiom.2019.09.003. View

17.

Hassan R, Thomas A, Alewine C, Le D, Jaffee E, Pastan I . Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. J Clin Oncol. 2016; 34(34):4171-4179. PMC: 5477819. DOI: 10.1200/JCO.2016.68.3672. View

18.

Hung Y, Chirieac L . Pathology of Malignant Pleural Mesothelioma. Thorac Surg Clin. 2020; 30(4):367-382. DOI: 10.1016/j.thorsurg.2020.08.007. View

19.

Travis W . The 2015 WHO classification of lung tumors. Pathologe. 2014; 35 Suppl 2:188. DOI: 10.1007/s00292-014-1974-3. View

20.

Osanai M, Takasawa A, Murata M, Sawada N . Claudins in cancer: bench to bedside. Pflugers Arch. 2016; 469(1):55-67. DOI: 10.1007/s00424-016-1877-7. View